183 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast PeerView

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

    Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.

    The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent educational grant from AstraZeneca.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Sandip Patel, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.
    Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.


    Faculty/Planner
    Tina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.
    Grant/Research Support from AstraZeneca and Bristol Myers Squibb.


    Faculty/Planner
    John V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.
    Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 58 min
    Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

    Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.

    Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
    Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.


    Faculty/Planner
    Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
    Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.


    Faculty/Planner
    Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.
    Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 53 min
    Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

    Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.

    A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
    Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
    Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
    Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.


    Faculty/Planner
    Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
    Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 1 hr 6 min
    Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

    Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.

    Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.


    Faculty/Planner
    Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
    Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
    Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.


    Faculty/Planner
    Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
    Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.


    Faculty/Planner
    Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taih

    • 54 min
    Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon Mutations: How to Navigate the Expanding Options and Increasing Complexity

    Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon Mutations: How to Navigate the Expanding Options and Increasing Complexity

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SKH865. CME/MOC/AAPA/IPCE credit will be available until March 20, 2025.

    Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.
    Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.


    Faculty/Planner
    Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.
    Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.


    Faculty/Planner
    Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
    Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.
    Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
    Stock Shareholder in Lilly.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers

    • 52 min
    Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic

    Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 7, 2025.

    Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through an educational grant from Bristol Myers Squibb.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 24 min

Top Podcasts In Science

Hiçbir Şey Tesadüf Değil
Podbee Media
Bi Aile Meselesi
Bi Aile Meselesi
Evrim Ağacı ile Bilime Dair Her Şey!
Evrim Ağacı
AkademikLink
AkademikLink
Hidden Brain
Hidden Brain, Shankar Vedantam
BBC Inside Science
BBC Radio 4

You Might Also Like

More by PeerView Press

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
PVI, PeerView Institute for Medical Education
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
PVI, PeerView Institute for Medical Education
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
PVI, PeerView Institute for Medical Education
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
PVI, PeerView Institute for Medical Education
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
PVI, PeerView Institute for Medical Education
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
PVI, PeerView Institute for Medical Education